| 1 |
Marti-aguado D, Clemente-sanchez A, Bataller R. Cigarette Smoking and Liver Diseases. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.016] [Reference Citation Analysis]
|
| 2 |
Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Reference Citation Analysis]
|
| 3 |
Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Reference Citation Analysis]
|
| 4 |
Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, Romero-Gómez M. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Front Immunol 2021;12:667354. [PMID: 34899679 DOI: 10.3389/fimmu.2021.667354] [Reference Citation Analysis]
|
| 5 |
Ayonrinde OT. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past. JHEP Rep 2021;3:100261. [PMID: 34036255 DOI: 10.1016/j.jhepr.2021.100261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
|
| 7 |
Maya-Miles D, Ampuero J, Gallego-Durán R, Dingianna P, Romero-Gómez M. Management of NAFLD patients with advanced fibrosis. Liver Int 2021;41 Suppl 1:95-104. [PMID: 34155801 DOI: 10.1111/liv.14847] [Reference Citation Analysis]
|
| 8 |
Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Rivera-Esteban J, Armandi A, Augustin S, Bugianesi E. Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. Liver Int 2021;41:1999-2008. [PMID: 34242466 DOI: 10.1111/liv.15013] [Reference Citation Analysis]
|
| 10 |
Ampuero J, Gallego-Durán R, Maya-Miles D, Montero R, Gato S, Rojas Á, Gil A, Muñoz R, Romero-Gómez M. Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. J Gastroenterol 2022. [PMID: 35325295 DOI: 10.1007/s00535-022-01860-0] [Reference Citation Analysis]
|
